Form 4: Intellia Therapeutics Executive Sells Shares for Tax Withholding

Michael P. Dube, VP and Chief Accounting Officer of Intellia Therapeutics, reported a transaction involving the sale of 2,641 shares of common stock to cover tax obligations upon the vesting of RSUs.

Summary

• Michael P. Dube, VP and Chief Accounting Officer at Intellia Therapeutics, Inc., engaged in a transaction on July 1, 2026.
• This transaction involved the sale of 2,641 shares of common stock.
• The sale was a mandatory 'sell-to-cover' to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The sale was executed at a weighted average price of $16.78 per share, with individual sales ranging from $16.78 to $17.12.
• Following this transaction, Dube beneficially owns 66,886 shares of common stock.
• This transaction is not considered a volitional trade by the reporting person.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral score because the transaction is a mandatory 'sell-to-cover' for tax purposes, not a volitional sale, and does not provide insight into the executive's view of the company's future performance.

Positives

• The transaction was a mandatory 'sell-to-cover' for tax withholding, indicating a standard procedure for RSU vesting and not a reflection of negative sentiment towards the stock.
• The reporting person retains a significant number of shares (66,886) after the transaction.

Negatives

• A total of 2,641 shares were sold, reducing the reporting person's direct holdings.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Management Comments

• "Represents a mandatory 'sell-to-cover' transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person."
• "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive."
• "Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price."

Industry Context

StockSavvy.ai notes that Form 4 filings reporting 'sell-to-cover' transactions for tax withholding are common in the biotechnology and pharmaceutical sectors, particularly following RSU vesting events. These are typically routine and not indicative of a change in management's fundamental view of the company's prospects.

Stakeholder Impact

• Shareholders: The sale of shares by an executive for tax purposes is a routine event and typically has minimal direct impact on the share price, as it is a pre-planned event related to compensation.

Next Steps

• The reporting person will provide full information regarding the number of shares sold at each separate price upon request.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, SEC Filing, Stock Sale, RSU Vesting, Tax Withholding, Beneficial Ownership, Executive Compensation